Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial-Reference-Cited by-同舟云学术

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Published:2013-01 Issue:1 Volume:24 Page:75-83
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Reck M.,Bondarenko I.,Luft A.,Serwatowski P.,Barlesi F.,Chacko R.,Sebastian M.,Lu H.,Cuillerot J.-M.,Lynch T.J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/1/75/13788707/mds213.pdf

Reference47 articles.

1. Treatment options for small cell lung cancer – do we have more choice?;Puglisi;Br J Cancer,2010

2. Staging and clinical prognostic factors for small-cell lung cancer;Argiris;Cancer J,2001

3. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results;Oze;PLoS One,2009

4. CTLA-4 can function as a negative regulator of T cell activation;Walunas;Immunity,1994

5. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation;Krummel;J Exp Med,1995

Cited by 547 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer;Respiratory Medicine and Research;2024-11

2. Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities;Experimental Hematology & Oncology;2024-08-05

3. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer;Nature Reviews Clinical Oncology;2024-07-04

4. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial;Nature Medicine;2024-05-22

5. Immunotherapy in the Treatment of Cancer: Today and Tomorrow;Current Molecular Biology Reports;2024-05-20